KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Equity (2016 - 2025)

Alnylam Pharmaceuticals' Return on Equity history spans 16 years, with the latest figure at 0.62% for Q4 2025.

  • For Q4 2025, Return on Equity rose 622.0% year-over-year to 0.62%; the TTM value through Dec 2025 reached 0.62%, up 622.0%, while the annual FY2025 figure was 0.73%, 289.0% down from the prior year.
  • Return on Equity reached 0.62% in Q4 2025 per ALNY's latest filing, up from 0.51% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 10.02% in Q4 2022 to a low of 22.69% in Q3 2024.
  • Average Return on Equity over 5 years is 1.89%, with a median of 0.95% recorded in 2021.
  • Peak YoY movement for Return on Equity: soared 2359bps in 2023, then plummeted -2447bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 1.27% in 2021, then skyrocketed by 889bps to 10.02% in 2022, then plummeted by -77bps to 2.28% in 2023, then tumbled by -346bps to 5.59% in 2024, then soared by 111bps to 0.62% in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Return on Equity are 0.62% (Q4 2025), 0.51% (Q3 2025), and 1.53% (Q2 2025).